Natera, Inc. (NTRA)

Natera's stock has been impacted by several events in the past six months. Natera reported revenue of $592.2 million in Q3 2025, beating analyst estimates, but missed on EPS. The company announced strong preliminary results for Q4 and full year 2025, expecting approximately $660 million and $2.3 billion in revenue, respectively. Natera launched the EDEN study, made an FDA submission for Signatera CDx, completed enrollment in its randomized ACES-EMB trial, and unveiled an AI model to enhance cancer recurrence risk assessment. Company insiders have sold a significant number of shares. Analysts have an average rating of "Moderate Buy" for NTRA, with a consensus target price around $249.20.

Natera experiences some demand seasonality, particularly in its Women's Health segment. The first quarter is generally a very strong volume quarter for Women's Health products, followed by a drop in Q2, with recovery observed in Q3 and Q4. This seasonality is primarily influenced by when individuals visit their OB/GYN for non-invasive prenatal testing. New account acquisitions are not significantly seasonal.

Natera, Inc. is a global diagnostics company specializing in cell-free DNA and other genetic testing technologies for clinical applications, operating within the Healthcare sector. The company's technology combines molecular biology techniques with bioinformatics software and artificial intelligence to detect cfDNA from various sources. Natera focuses on reproductive health with products like Panorama, Vistara, Horizon, Spectrum, Anora, and non-invasive paternity testing. In oncology, key offerings include Signatera and Altera. For organ transplantation, products such as Prospera and Renasight are available. Additionally, Natera offers Constellation, a cloud-based software platform.

Natera operates certified clinical laboratories in Austin, Texas, and San Carlos, California, serving healthcare providers, hospitals, fertility clinics, and biopharmaceutical partners across the United States and in international markets. Over 93% of Natera's revenue in 2020 was generated within the U.S.

In the past year, Natera has demonstrated a commitment to advancing genetic testing and precision medicine through clinical developments and strong financial performance. The launch of the EDEN study, FDA submission for Signatera CDx, and completion of enrollment in the Prospera heart transplant trial highlight the company's focus on innovation. Natera also reported strong revenue growth in its Q1 and Q3 2025 earnings, and positive preliminary results for Q4 and full year 2025. There is no readily available information indicating significant negative events impacting Natera's brand reputation within the past year.

Institutional investors hold a substantial portion of Natera, Inc. stock, ranging from approximately 82.53% to 99.9%. Major institutional owners include Vanguard Group Inc., Price T Rowe Associates Inc /md/, JPMorgan Chase & Co, BlackRock, Inc., Farallon Capital Management Llc, and others. Company insiders collectively own 5.63% of the company's stock.